Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00352222
Other study ID # S2015
Secondary ID MTE-E-0301
Status Completed
Phase Phase 3
First received July 12, 2006
Last updated September 25, 2008
Start date January 2004
Est. completion date February 2007

Study information

Verified date September 2008
Source Boston Scientific Corporation
Contact n/a
Is FDA regulated No
Health authority Netherlands: Independent Ethics CommitteeBelgium: Federal Agency for Medicines and Health Products, FAMHPCanada: Health CanadaJapan: Pharmaceuticals and Medical Devices Agency
Study type Interventional

Clinical Trial Summary

To obtain additional data on safety and efficacy of the Express stent implantation in the treatment of stenosed or occlusive atherosclerotic disease (de novo or restenotic lesions) in the iliac arteries (common or external).


Description:

This study was conducted to provide additional data on the safety and efficacy of the Express™ Vascular LD stent, particularly with regard to the long-term patency in iliac arteries. The study would provide data on angiographic endpoints and clinical outcomes at 30 days, 6 months, and at 12 and 24 months post implantation in atherosclerotic lesions in iliac arteries. The data obtained in this study with the use of the Express™ Vascular LD stent was compared with historical data obtained from the use of the Palmaz balloon-expandable stent. The Palmaz balloon expandable stent has been chosen as the control device because it is currently the only FDA-approved balloon-expandable stent for use in the percutaneous treatment of atherosclerotic disease in iliac arteries.

The Palmaz balloon-expandable stent is no longer commercialized in Europe. Therefore a randomized study with the Palmaz balloon-expandable stent was not feasible. In addition, there are no ongoing or published randomized trials describing performance of a newer version of the Palmaz stent in iliac atherosclerotic lesions. In order to adequately compare the efficacy data of the ExpressTM Vascular LD stent with the efficacy data of the Palmaz balloon-expandable stent, the same efficacy parameter as in the publication on the Palmaz balloon-expandable stent was measured in this study: % mean loss of the luminal diameter at 6 months post-procedure.

The findings of the longer-term Follow-Up assessments at 12 and 24 months will be presented as the results from these assessments become available.


Recruitment information / eligibility

Status Completed
Enrollment 150
Est. completion date February 2007
Est. primary completion date July 2005
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- chronic symptomatic atherosclerotic disease in the iliac arteries (Fontaine Class IIa, IIb, and III)

- atherosclerotic de novo or restenotic lesions in the common and/or external iliac artery.

- baseline diameter stenosis of > or = 50%

- reference vessel diameter > or = 5mm and < or = 10mm

- at least one sufficient ipsilateral infrapopliteal run-off

- length of diseased segment(s) < or = 10cm and can be treated with maximally two overlapping Express Vascular LD Stents.

- multiple target lesions of the iliac arteries in the same patient can be included provided if each target lesion is compliant with the antiographic inclusion criteria and non-compliant with any of the antiographic exclusion criteria, target lesions are not located in the same target axis, and all target lesions can be treated during the same procedure.

Exclusion Criteria:

- chronic symptomatic atherosclerotic disease classified as fontaine Class I or IV

- acute leg ischemia

- pregnants patients

- patients with uncorrected bleeding disorders (platelets < 150 000/mm3 or > 450 000 mm3, or patient who cannot receive anticoagulation or antiplatelet aggregation therapy

- patient with known allergy to stainless steel

- known anaphylactoid or other non-anaphylactic reactions to contrast agents that cannot be adequately premedicated prior to the index procedure

- life-expectancy of less than 24 months due to other medical co-morbid condition that could limit patient's ability to participate in the study, the patient's compliance with the follow-up requirements or impact the scientific integrity of the study

- patient currently participating in another study that has not yet completed the primary endpoint or that clinically interferes with the endpoint of this study

- patients who have already participated in this study

- patients with prior or planned bypass surgery of the target vessel

- patient with prior stent placement in the target vessel

- patient with any previous coronary intervention within the last 30 days before enrollment into this study or patients with planned coronary intervention within 30 days after enrollment into this study.

- patients in whom the origin of the profunda femoris and superficial femoral artery is occluded in the limb supplied by the iliac artery to be treated without planned surgical repair

- patients with heavily calcified and excessive tortuous lesions at the target site as determined by angiography

- patients with target lesion which is within or adjacent to the proximal or distal segment of an aneurysm

- patients with persistent, acute intraluminal thrombus of the proposed target lesion site post-thrombolytic therapy

- patients with perforated vessels as evidenced by extravasation of contrast media

- patients with multiple lesions in the same target vessels.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Device:
stent implantation


Locations

Country Name City State
Belgium Limburgs Vaatcentrum Ziekenhuis Oost-Limburg Genk
Belgium Sint Trudo Hospital Sint Truiden
Canada CHUM- Notre Dame Hospital Montreal Quebec
Czech Republic General Teaching Hospital Prague Praha
Czech Republic Institute for Clinical and Experimental Medicine (IKEM) Praha
Netherlands Sint Antonius Hospital Nieuwegein CM
Poland University Hospital of Krakow Krakow
Poland University School of Medicine Lublin
Poland Center of Diagnostic Imaging and Vascular Disease Treatment Szczecin
Poland Samodzielny Publiczny Centraln Szpital Warszawa

Sponsors (2)

Lead Sponsor Collaborator
Boston Scientific Corporation KIKA

Countries where clinical trial is conducted

Belgium,  Canada,  Czech Republic,  Netherlands,  Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Angiographic mean percent loss of luminal diameter at 6 months post-procedure defined as ((post-procedure MLD - Follow-up MLD)/Post-procedure MLD) X 100
Secondary hemodynamic success at hospital discharge, 30 days and 6, 12 and 24 months post-procedure, angiographic binary restenosis at 6 mont
See also
  Status Clinical Trial Phase
Completed NCT03826043 - THrombo-Embolic Event in Onco-hematology N/A
Recruiting NCT04398628 - ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Completed NCT05426564 - Exploratory Assessment of the Quantra® System in Adult ECMO Patients
Not yet recruiting NCT05830916 - Diagnostic Role of Antiphospholipid Antibodies and Microparticles in Immune Thrombocytopenic Patients With Thrombosis
Recruiting NCT02972385 - Pharmacogenomics of Warfarin in Hispanics and Latinos
Completed NCT02917213 - Imaging Silent Brain Infarct And Thrombosis in Acute Myocardial Infarction
Completed NCT02526628 - Thrombosis and Neurocognition in Klinefelter Syndrome
Completed NCT02439190 - CV004-007 Thrombosis Chamber Study Phase 1
Completed NCT02341638 - Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects Phase 1
Completed NCT01855516 - Partial Thromboplastin Time After 72 Hours of Antithrombotic Prophylaxis Using Unfractionated Heparin N/A
Unknown status NCT00983112 - Evicel Study on the Peri-operative Bleeding in Total Knee Prothesis Surgery Phase 4
Completed NCT00412464 - Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis Phase 1
Completed NCT00346424 - Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Central Catheters Phase 3
Completed NCT00479362 - Anticoagulant Therapy During Pacemaker Implantation Phase 4
Completed NCT00143715 - Oral Vitamin K for Warfarin Associated Coagulopathy Phase 3
Terminated NCT00303420 - Alteplase for Blood Flow Restoration in Hemodialysis Catheters Phase 4
Completed NCT00039858 - Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin Phase 4
Completed NCT00007410 - Genetic Architecture of Plasma T-PA and PAI-1 N/A
Completed NCT00000538 - Dietary Effects on Lipoproteins and Thrombogenic Activity Phase 3
Completed NCT00005436 - Lupus Cohort--Thrombotic Events and Coronary Artery Disease N/A